DUBLIN–(BUSINESS WIRE)–The “Global
Dravet Syndrome Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.
Dravet Syndrome Pipeline Highlights – 2019 provides most up-to-date
information on key pipeline products in the global Dravet Syndrome
market. It covers emerging therapies for Dravet Syndrome in active
clinical development stages including early and late stage clinical
trials. The pipeline data presented in this report helps executives for
tracking competition, identifying partners, evaluating opportunities,
formulating business development strategies, and executing in-licensing
and out-licensing deals.
Clinical Trial Stages:
The report provides Dravet Syndrome pipeline products by clinical trial
stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Dravet Syndrome pipeline products by their dominant
mechanism of action/drug class. This helps executives categorize
products based on their drug class and also assess the strengths and
weaknesses of compounds.
Company:
The report provides Dravet Syndrome pipeline products by the company.
Short-term Launch Highlights:
Find out which Dravet Syndrome pipeline products will be launched in the
US and Ex-US till 2024.
Key Topics Covered:
1. Dravet Syndrome Pipeline by Stages
2. Dravet Syndrome Phase 3 Clinical Trial Insights
3. Dravet Syndrome Phase 2 Clinical Trial Insights
4. Dravet Syndrome Phase 1 Clinical Trial Insights
5. Dravet Syndrome Preclinical Research Insights
6. Dravet Syndrome Discovery Stage Insights
7. Appendix
8. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/glm4sd
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs, Clinical
Trials